Financhill
Buy
66

VIGL Quote, Financials, Valuation and Earnings

Last price:
$7.99
Seasonality move :
49.22%
Day range:
$7.95 - $7.97
52-week range:
$1.31 - $7.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.71x
Volume:
1.6M
Avg. volume:
2.6M
1-year change:
82.38%
Market cap:
$372M
Revenue:
--
EPS (TTM):
-$2.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VIGL
Vigil Neuroscience
-- -$0.47 -- -9.62% $9.52
AMGN
Amgen
$8.9B $5.23 5.67% 279.07% $314.27
GILD
Gilead Sciences
$7B $1.95 -0.13% 51.38% $116.77
HOOK
HOOKIPA Pharma
$3.4M -$0.64 161.63% -59.87% $2.00
POAI
Predictive Oncology
$1.5M -- -25.85% -- --
SWTX
SpringWorks Therapeutics
$74.9M -$0.97 22.87% -79.63% $47.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VIGL
Vigil Neuroscience
$7.97 $9.52 $372M -- $0.00 0% --
AMGN
Amgen
$290.52 $314.27 $156.2B 26.51x $2.38 3.19% 4.61x
GILD
Gilead Sciences
$111.73 $116.77 $139B 23.52x $0.79 2.79% 4.90x
HOOK
HOOKIPA Pharma
$1.25 $2.00 $15.2M -- $0.00 0% 1.68x
POAI
Predictive Oncology
$0.83 -- $7.4M -- $0.00 0% 3.85x
SWTX
SpringWorks Therapeutics
$46.99 $47.00 $3.5B -- $0.00 0% 15.92x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VIGL
Vigil Neuroscience
-- 10.653 -- --
AMGN
Amgen
90.24% -0.268 34.26% 0.74x
GILD
Gilead Sciences
56.56% 0.135 17.9% 1.00x
HOOK
HOOKIPA Pharma
-- 3.199 -- 2.92x
POAI
Predictive Oncology
-- 0.261 -- 0.68x
SWTX
SpringWorks Therapeutics
-- 1.839 -- 3.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VIGL
Vigil Neuroscience
-- -$23.5M -- -- -- -$24.2M
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
GILD
Gilead Sciences
$5.1B $2.5B 13.82% 32.29% 28.63% $1.7B
HOOK
HOOKIPA Pharma
-- -$17.5M -105.09% -105.43% -769.81% $32K
POAI
Predictive Oncology
$65.2K -$2.3M -529.75% -557.45% -2073.29% -$985.8K
SWTX
SpringWorks Therapeutics
$45.6M -$80.5M -49.69% -49.69% -167.44% -$68.8M

Vigil Neuroscience vs. Competitors

  • Which has Higher Returns VIGL or AMGN?

    Amgen has a net margin of -- compared to Vigil Neuroscience's net margin of 21.23%. Vigil Neuroscience's return on equity of -- beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About VIGL or AMGN?

    Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 19.5%. On the other hand Amgen has an analysts' consensus of $314.27 which suggests that it could grow by 8.18%. Given that Vigil Neuroscience has higher upside potential than Amgen, analysts believe Vigil Neuroscience is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    VIGL
    Vigil Neuroscience
    0 8 0
    AMGN
    Amgen
    11 14 2
  • Is VIGL or AMGN More Risky?

    Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.876%.

  • Which is a Better Dividend Stock VIGL or AMGN?

    Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.19% to investors and pays a quarterly dividend of $2.38 per share. Vigil Neuroscience pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios VIGL or AMGN?

    Vigil Neuroscience quarterly revenues are --, which are smaller than Amgen quarterly revenues of $8.1B. Vigil Neuroscience's net income of -$22.4M is lower than Amgen's net income of $1.7B. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while Amgen's PE ratio is 26.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 4.61x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M
    AMGN
    Amgen
    4.61x 26.51x $8.1B $1.7B
  • Which has Higher Returns VIGL or GILD?

    Gilead Sciences has a net margin of -- compared to Vigil Neuroscience's net margin of 19.72%. Vigil Neuroscience's return on equity of -- beat Gilead Sciences's return on equity of 32.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
    GILD
    Gilead Sciences
    76.9% $1.04 $44B
  • What do Analysts Say About VIGL or GILD?

    Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 19.5%. On the other hand Gilead Sciences has an analysts' consensus of $116.77 which suggests that it could grow by 4.51%. Given that Vigil Neuroscience has higher upside potential than Gilead Sciences, analysts believe Vigil Neuroscience is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    VIGL
    Vigil Neuroscience
    0 8 0
    GILD
    Gilead Sciences
    15 11 0
  • Is VIGL or GILD More Risky?

    Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

  • Which is a Better Dividend Stock VIGL or GILD?

    Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.79% to investors and pays a quarterly dividend of $0.79 per share. Vigil Neuroscience pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

  • Which has Better Financial Ratios VIGL or GILD?

    Vigil Neuroscience quarterly revenues are --, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Vigil Neuroscience's net income of -$22.4M is lower than Gilead Sciences's net income of $1.3B. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 23.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 4.90x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M
    GILD
    Gilead Sciences
    4.90x 23.52x $6.7B $1.3B
  • Which has Higher Returns VIGL or HOOK?

    HOOKIPA Pharma has a net margin of -- compared to Vigil Neuroscience's net margin of -769.81%. Vigil Neuroscience's return on equity of -- beat HOOKIPA Pharma's return on equity of -105.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
    HOOK
    HOOKIPA Pharma
    -- -$1.23 $34.1M
  • What do Analysts Say About VIGL or HOOK?

    Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 19.5%. On the other hand HOOKIPA Pharma has an analysts' consensus of $2.00 which suggests that it could grow by 60%. Given that HOOKIPA Pharma has higher upside potential than Vigil Neuroscience, analysts believe HOOKIPA Pharma is more attractive than Vigil Neuroscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    VIGL
    Vigil Neuroscience
    0 8 0
    HOOK
    HOOKIPA Pharma
    0 1 0
  • Is VIGL or HOOK More Risky?

    Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HOOKIPA Pharma has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.599%.

  • Which is a Better Dividend Stock VIGL or HOOK?

    Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HOOKIPA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vigil Neuroscience pays -- of its earnings as a dividend. HOOKIPA Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VIGL or HOOK?

    Vigil Neuroscience quarterly revenues are --, which are smaller than HOOKIPA Pharma quarterly revenues of $2M. Vigil Neuroscience's net income of -$22.4M is lower than HOOKIPA Pharma's net income of -$15.4M. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while HOOKIPA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 1.68x for HOOKIPA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M
    HOOK
    HOOKIPA Pharma
    1.68x -- $2M -$15.4M
  • Which has Higher Returns VIGL or POAI?

    Predictive Oncology has a net margin of -- compared to Vigil Neuroscience's net margin of -2214.55%. Vigil Neuroscience's return on equity of -- beat Predictive Oncology's return on equity of -557.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
    POAI
    Predictive Oncology
    59.1% -$0.34 -$145.8K
  • What do Analysts Say About VIGL or POAI?

    Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 19.5%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 260.58%. Given that Predictive Oncology has higher upside potential than Vigil Neuroscience, analysts believe Predictive Oncology is more attractive than Vigil Neuroscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    VIGL
    Vigil Neuroscience
    0 8 0
    POAI
    Predictive Oncology
    0 0 0
  • Is VIGL or POAI More Risky?

    Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.176, suggesting its more volatile than the S&P 500 by 17.559%.

  • Which is a Better Dividend Stock VIGL or POAI?

    Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vigil Neuroscience pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VIGL or POAI?

    Vigil Neuroscience quarterly revenues are --, which are smaller than Predictive Oncology quarterly revenues of $110.3K. Vigil Neuroscience's net income of -$22.4M is lower than Predictive Oncology's net income of -$2.4M. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 3.85x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M
    POAI
    Predictive Oncology
    3.85x -- $110.3K -$2.4M
  • Which has Higher Returns VIGL or SWTX?

    SpringWorks Therapeutics has a net margin of -- compared to Vigil Neuroscience's net margin of -169.47%. Vigil Neuroscience's return on equity of -- beat SpringWorks Therapeutics's return on equity of -49.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
    SWTX
    SpringWorks Therapeutics
    92.82% -$1.11 $417.4M
  • What do Analysts Say About VIGL or SWTX?

    Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 19.5%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $47.00 which suggests that it could grow by 0.02%. Given that Vigil Neuroscience has higher upside potential than SpringWorks Therapeutics, analysts believe Vigil Neuroscience is more attractive than SpringWorks Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    VIGL
    Vigil Neuroscience
    0 8 0
    SWTX
    SpringWorks Therapeutics
    0 3 0
  • Is VIGL or SWTX More Risky?

    Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.589%.

  • Which is a Better Dividend Stock VIGL or SWTX?

    Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vigil Neuroscience pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VIGL or SWTX?

    Vigil Neuroscience quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $49.1M. Vigil Neuroscience's net income of -$22.4M is higher than SpringWorks Therapeutics's net income of -$83.2M. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 15.92x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M
    SWTX
    SpringWorks Therapeutics
    15.92x -- $49.1M -$83.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 52x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
60
AEVA alert for Jul 2

Aeva Technologies [AEVA] is up 7.78% over the past day.

Sell
44
PRGS alert for Jul 2

Progress Software [PRGS] is down 2.94% over the past day.

Sell
46
NAIL alert for Jul 2

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 3.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock